Welcome to SwanBio Therapeutics
SwanBio Therapeutics is a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is born of curiosity, collaboration, and compassion.
Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.
SwanBio Therapeutics is dedicated to developing genetic medicines for the treatment of serious neurological diseases with significant unmet need.
Nearly 27 million Americans are currently afflicted by one of over 1,000 neurological diseases, which lead to tremendous suffering, life-limiting disability, and expansive societal burden. The impact of these diseases on patients and their families, friends, and communities affects more than 100 million Americans.
SwanBio Therapeutics brings together the vast experience of the unique combination of the founders in science, technology, clinical applications, and manufacturing.
SwanBio Therapeutics is funded by Syncona Ltd., a leading FTSE250 company that invests in, and builds, global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating attractive returns for shareholders. More >>